These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20093504)

  • 1. Can the effect of antiangiogenic treatments be monitored and quantified noninvasively by using contrast-enhanced US?
    Forsberg F
    Radiology; 2010 Feb; 254(2):317-8. PubMed ID: 20093504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
    Guibal A; Taillade L; Mulé S; Comperat E; Badachi Y; Golmard JL; Le Guillou-Buffello D; Rixe O; Bridal SL; Lucidarme O
    Radiology; 2010 Feb; 254(2):420-9. PubMed ID: 20093514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can contrast-enhanced US with targeted microbubbles monitor the response to antiangiogenic therapies?
    Kruskal JB
    Radiology; 2008 Feb; 246(2):339-40. PubMed ID: 18227533
    [No Abstract]   [Full Text] [Related]  

  • 4. Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.
    Sirsi SR; Flexman ML; Vlachos F; Huang J; Hernandez SL; Kim HK; Johung TB; Gander JW; Reichstein AR; Lampl BS; Wang A; Hielscher AH; Kandel JJ; Yamashiro DJ; Borden MA
    Ultrasound Med Biol; 2012 Jun; 38(6):1019-29. PubMed ID: 22425376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
    Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
    Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.
    Murukesh N; Dive C; Jayson GC
    Br J Cancer; 2010 Jan; 102(1):8-18. PubMed ID: 20010945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy.
    Sorace AG; Saini R; Mahoney M; Hoyt K
    J Ultrasound Med; 2012 Oct; 31(10):1543-50. PubMed ID: 23011617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Science to practice: Will improved assessment of response to antiangiogenic therapies be achieved with contrast-enhanced gray-scale US?
    Kruskal JB
    Radiology; 2006 Jul; 240(1):1-2. PubMed ID: 16793969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
    Jia Z; Zhang J; Wei D; Wang L; Yuan P; Le X; Li Q; Yao J; Xie K
    Cancer Res; 2007 May; 67(10):4878-85. PubMed ID: 17510417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast-enhanced Ultrasound Imaging of Antiangiogenic Tumor Therapy.
    Klotz LV; Clevert DA; Scheckinger S; Strieth S; Eichhorn ME
    Anticancer Res; 2015 May; 35(5):2571-6. PubMed ID: 25964532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New medications; bevacizumab].
    Cohen AF; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer.
    Ellis LM
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S1-7. PubMed ID: 17145519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment.
    Rix A; Lederle W; Siepmann M; Fokong S; Behrendt FF; Bzyl J; Grouls C; Kiessling F; Palmowski M
    Eur J Radiol; 2012 Oct; 81(10):2710-6. PubMed ID: 22093958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
    Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
    Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
    Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
    J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.